Inventor
BENSUSSAN ARMAND
FR20 patents
⚠️ This page may combine multiple inventors who share the name “BENSUSSAN ARMAND”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INST NAT SANTE RECH MED
9 patentsUS7919085B2Apr 5, 2011
Means for the diagnosis and therapy of CTCL
INST NAT SANTE RECH MED14 citations90
US7399595B2Jul 15, 2008
Means for the diagnosis and therapy of CTCL
INST NAT SANTE RECH MED11 citations90
US10662253B2May 26, 2020
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity
INST NAT SANTE RECH MED5 citations80
US10208124B2Feb 19, 2019
Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
INST NAT SANTE RECH MED4 citations67
US11685792B2Jun 27, 2023
Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity
INST NAT SANTE RECH MED1 citations58
US11186635B2Nov 30, 2021
Monoclonal antibodies binding to the CD160 transmembrane isoform
INST NAT SANTE RECH MED0 citations54
US12319745B2Jun 3, 2025
Antibodies having specificity for CD38 and uses thereof
INST NAT SANTE RECH MED0 citations47
US11365392B2Jun 21, 2022
Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof
INST NAT SANTE RECH MED0 citations44
US11198851B2Dec 14, 2021
Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof
INST NAT SANTE RECH MED0 citations44
BENSUSSAN ARMAND
3 patentsUS8518655B2Aug 27, 2013
Means for the diagnosis and therapy of CTCL
BENSUSSAN ARMAND9 citations80
US8268308B2Sep 18, 2012
Means for the diagnosis and therapy of CTCL
BENSUSSAN ARMAND10 citations80
US8444978B2May 21, 2013
Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
BENSUSSAN ARMAND2 citations55